Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin 147 and PCSK9 inibitor - Novo Nordisk

X
Drug Profile

Insulin 147 and PCSK9 inibitor - Novo Nordisk

Alternative Names: Insulin and PCSK9i hybrid; Insulin-147

Latest Information Update: 16 Feb 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones; Peptides
  • Mechanism of Action Ornithine decarboxylase stimulants; PCSK9 protein inhibitors; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Diabetes mellitus

Most Recent Events

  • 16 Feb 2022 Discontinued - Phase-I for Diabetes mellitus in Denmark, as of February 2022 (SC) (Novo Nordisk pipeline, February 2022)
  • 24 Nov 2021 Insulin 147 is available for licensing as of 17 Nov 2021. https://www.novonordisk.com/partnering-and-open-innovation/contact-us-about-partnering.html
  • 31 Jan 2020 Phase-I clinical trials in Diabetes mellitus in Denmark (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top